profit from every $100 of sales.
$0$100
OKYO Pharma
$1.40-1.41% today
-46.2% in 1 year
1-year low $1.281-year high $3.11
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What OKYO Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$4.71 million of profit last year.
SalesProfit
OKYO Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OKYO Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OKYO Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -6 | -13 | -16 | -7 | |
| -6 | -13 | -16 | -7 | |
| -5 | -13 | -17 | -5 | |
| -0.36 | -0.61 | -0.57 | -0.12 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4 | 5 | 2 | 4 |
| Cash | 3 | 4 | 1 | 2 |
| Total debt | 0 | 2 | – | – |
| Total liabilities | 1 | 7 | 7 | 9 |
| 3 | -2 | -6 | -6 | |
| 798 | 22 | 29 | 39 | |
| -166.7% | -6,435.8% | – | – | |
| -184.3% | 646.4% | 286.2% | 84.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -8 | -9 | -2 | |
| 0 | 0 | – | 0 | |
| -5 | -8 | -9 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- -17.9×
- –
- –
- –
- -2.5%
- -6.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 154.2%
- -1,614.8%
- 102.9%
- -99.3%
- 204.2%
- –
Growth
- –
- –
- +80.9%
- –
- +39.8%
Financial health
- 0.4×
- -0.05
- 4.0%
- -33.2×
- 0.58
- 0.58
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 952
Bottom 20%of 883
Bottom 28%of 985
What analysts expect
- Average price target
- $7.00
- Range
- $7.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Jan 30, 2026 | -0.01 | -0.07 | +85.7% |
| Jan 29, 2025 | -0.08 | – | – |
| May 13, 2024 | -0.30 | – | – |
| Oct 1, 2023 | -0.00 | – | – |
| Mar 31, 2023 | -0.00 | – | – |
| Oct 1, 2022 | -0.00 | – | – |
| Mar 31, 2022 | -0.47 | – | – |
| Sep 30, 2021 | -0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
3No pass
Philip Fisher
39No pass
Peter Lynch
–Not enough data
Joel Greenblatt
69Pass
Charlie Munger
46No pass
Terry Smith
42No pass
Questions about OKYO Pharma
Is OKYO Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OKYO Pharma AI analysis
What does OKYO Pharma do?
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. It is in Biotechnology.
Does OKYO Pharma pay a dividend?
No. OKYO Pharma does not pay a dividend at the moment.
Is OKYO Pharma stock halal?
Yes. OKYO Pharma passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has OKYO Pharma stock done over the past year?
Down 46.2% over the past twelve months, to $1.40. It traded between $1.28 and $3.11 and is 55.0% below its high.
Who are OKYO Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OKYO Pharma's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.